GET THE APP

Plasma rich in growth factors in eye drops for the treatment of o | 52415
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

+44 1223 790975

Plasma rich in growth factors in eye drops for the treatment of ocular surface disease in patients with glaucoma


5th International Conference on Clinical & Experimental Ophthalmology

August 04-06, 2015 Valencia, Spain

Ronald Sanchez Avila and Jesus Merayo Lloves

Posters-Accepted Abstracts: J Clin Exp Ophthalmol

Abstract :

Purpose: To evaluate the effectiveness that has the eye drops plasma rich in growth factors (PRGF) for the treatment of ocular
surface diseases (OSD) in patients with glaucoma.
Material & Methods: Longitudinal, observational and descriptive study included 6 patients diagnosed with open-angle
glaucoma who received surgical treatment (EPNP and or trabeculectomy) and medical (1-3 hypotensive eye drops) to control
IOP (Intraocular pressure) which developed different ESD (Dry Eye Syndrome: Evaporative and or production shortfall, corneal
ulcers, limbal stem cell deficiency, viral keratitis) unresponsive to conventional treatment. The variables analyzed were: VAS
(Visual Analog Scale: Frequency and severity of symptoms), dry eye Psychometric Survey (OSDI: Ocular Surface Disease Index)
Visual acuity (VA) far (LogMAR), tear breakup time (TBUT), Schirmer test and IOP; such measures were taken before starting
treatment with PRGF, the next week, month and in subsequent visits, patients were followed for nearly a year.
Results: Patients was aged between 58 and 79 years (mean age, 71±7.2). Treatment cycles with PRGF were between 2 and 6 (1
cycle=6 weeks). They target the AV (logMAR) improved 44.5% (p=0.012), the test OSDI decreased 58.5% (p=0.027), the VAS
in frequency was decreased 53.5% (p=0.026), the VAS in severity decreased 44.57% (p=0.027) and IOP decreased by 16.5%
(p=0.010); TBUT and Schirmer test improving trend was also evident. One patient reported itching in both eyes as a side effect
(SE) but continued with the treatment until the end and the remaining patients reported no SE.
Conclusions: In patients with glaucoma and have ESD unresponsive to conventional treatments can now use the eye drops
PRGF showing clinical improvement and reduction of IOP.

Biography :

Ronald Sanchez Avila completed his training as a physician (National University of Colombia). He has completed Postgraduate studies in R&D of drugs, Health
Management. Currently he is completing his training as an ophthalmologist at the Hospital Universitario Central de Asturias, and is a Doctoral candidate to the research of
Ophthalmology and Vision Sciences (Univesidad of Oviedo, Eye Research Foundation, Ophthalmological Institute Fernandez-Vega). Results of his research have been
presented at national and international congresses ophthalmology.

Top